Moxidectin
Sponsors
Wyeth is now a wholly owned subsidiary of Pfizer, Medicines Development for Global Health, Pfizer, Jennifer Keiser, Washington University School of Medicine
Conditions
Ascaris Lumbricoides InfectionHealthyHookworm InfectionsInfectionLoiasisLymphatic FilariasisOnchocerciasisOnchocerciasis
Paediatrics
Phase 1
Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin
CompletedNCT00736697
Start: 2008-11-30End: 2009-05-31Updated: 2011-02-15
Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women
CompletedNCT00751764
Start: 2008-11-30End: 2009-09-30Target: 12Updated: 2010-09-16
Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects
CompletedNCT00856362
Start: 2009-04-30End: 2009-09-30Target: 38Updated: 2010-09-16
Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers
CompletedNCT03012828
Start: 2017-01-31End: 2017-05-31Updated: 2019-03-14
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
CompletedNCT03962062
Start: 2021-03-29End: 2022-09-28Updated: 2025-09-05
Determination of a Dose of Moxidectin in Individuals < 12 Years of Age
Active, not recruitingPACTR201907565746388
Start: 2020-01-06Target: 36Updated: 2026-08-03
Phase 2
Pediatric Pharmacokinetics And Safety Study Of Moxidectin
WithdrawnNCT01035619
Start: 2011-04-30End: 2011-04-30Updated: 2012-03-29
Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
CompletedNCT04056325
Start: 2019-11-27End: 2021-04-30Updated: 2024-12-09
A clinical phase IIa randomized, ascending dose, placebo-controlled, assessor-blind, safety, tolerability and efficacy study of orally administered Moxidectin in subjects with microfilaraemic Loa loa infection
RecruitingPACTR202303704849277
Start: 2023-04-16Target: 165Updated: 2026-08-03
Phase 3
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
CompletedNCT00790998
Start: 2009-04-30End: 2012-05-31Updated: 2018-01-31
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Active, not recruitingNCT03876262
Start: 2021-05-03End: 2026-01-01Updated: 2025-12-23
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
CompletedNCT04311671
Start: 2021-05-03End: 2024-09-27Updated: 2026-03-03
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Active, not recruitingPACTR202003567524647
Start: 2021-02-15Target: 12500Updated: 2026-08-03
Moxidectin for LF, Cote d'Ivoire (DOLF)
CompletedNCT04410406
Start: 2020-08-20End: 2024-10-01Updated: 2026-01-29